Japan-Only Orphan Drugs Available for Export: A Guide for Rare Disease Treatment Centres

The Orphan Drug Asymmetry Between Japan and Other Markets

Orphan drug designation varies significantly by jurisdiction. A medicine that carries orphan drug status in the European Union or United Kingdom—meaning it is approved only for rare disease indications with a limited patient population—may be a widely available, standard-approved product in Japan, and vice versa.

This regulatory asymmetry creates a practical sourcing opportunity. Japan’s Ministry of Health, Labour and Welfare (MHLW) has maintained an orphan drug designation programme since 1993, resulting in an extensive list of approved products for rare and difficult-to-treat conditions. Many of these products are manufactured exclusively or primarily in Japan, making Japanese exporters a critical part of the global supply chain for rare disease treatment.

For international rare disease treatment centres, hospital pharmacies, and specialist procurement teams, Japan represents a high-quality, GMP-compliant source for medicines that may be difficult or impossible to obtain locally.

How Japan’s Orphan Drug System Works

Japan’s orphan drug designation programme, administered by MHLW, applies to medicines intended for diseases affecting fewer than 50,000 patients domestically. Designated orphan drugs receive regulatory incentives including expedited review and extended data exclusivity.

Importantly, once approved by PMDA, Japan-designated orphan drugs become part of the standard approved product base and are available through the normal pharmaceutical distribution system. This means they can be sourced by qualified exporters for international supply—subject to the destination country’s importation framework.

Examples of the Japan–UK/EU Orphan Drug Asymmetry

The following examples illustrate how the same compound can have different regulatory status in Japan versus other markets:

Chenodeoxycholic Acid

In Japan, chenodeoxycholic acid is approved as a standard treatment for cholesterol gallstones and related conditions. In the European Union and United Kingdom, it holds orphan drug designation for cerebrotendinous xanthomatosis (CTX), a rare inherited metabolic disorder. UK and EU rare disease centres seeking a reliable supply of chenodeoxycholic acid can source Japanese-manufactured product through qualified exporters operating under GDP-compliant supply chains.

Dantrolene Sodium

Dantrolene sodium (brand name Dantrium) was designated as an orphan drug in Japan for malignant hyperthermia and malignant syndrome, and has been approved and distributed through OrphanPacific, one of Japan’s specialist rare disease pharmaceutical companies. It is used in anaesthesia departments internationally and may be sourced from Japan where local supply is constrained.

Pirfenidone (Pirespa)

Pirfenidone for idiopathic pulmonary fibrosis received Japanese approval under the orphan drug framework and was an early global approval of this compound. While pirfenidone has since received broader international approval, Japan-origin stock remains relevant for markets where specific formulations or supply constraints apply.

Baclofen (Intrathecal)

Intrathecal baclofen for severe spastic paralysis received orphan designation in Japan and is approved for a range of underlying conditions including cerebral palsy, multiple sclerosis, and post-traumatic spinal injury. Japanese-manufactured formulations may be accessed by specialist neurology and rehabilitation centres internationally.

Therapeutic Areas with Japan-Origin Orphan Drug Relevance

• Rare metabolic disorders: Urea cycle defects, lysosomal storage diseases, amino acid metabolism disorders
• Neurology: Spinocerebellar ataxia, ALS, myasthenia gravis, progressive myoclonus epilepsy
• Haematology: Rare coagulation factor deficiencies, aplastic anaemia treatments
• Infectious disease: Hansen’s disease (leprosy) treatments, rare parasitic infections
• Oncology: Rare leukaemia subtypes, lymphangioma, certain solid tumours
• Pulmonology: Primary pulmonary hypertension, idiopathic pulmonary fibrosis

Sourcing Japan-Designated Orphan Drugs: Key Requirements

International procurement of Japan-origin orphan drugs requires attention to the following:

• Destination country importation framework: Most regulated markets have a mechanism for accessing unlicensed or unregistered medicines for rare disease patients (e.g., UK Specials, Australian SAS, Singapore SAR). Confirm the applicable pathway before initiating procurement.
• GMP documentation: Japan is a PIC/S member. Japanese manufacturers operate under GMP standards recognised by regulatory authorities in over 50 countries.
• Certificate of Origin (CoO): Required by most destination country customs and regulatory authorities.
• GDP-compliant logistics: Cold chain requirements apply to many biologics and injectables. Ensure the exporter can provide temperature-controlled packaging and data loggers.
• Lead times: Rare disease products may have longer lead times than standard ethical medicines. Initiate procurement well in advance of clinical need.

Finding Japan-Approved Orphan Drugs: J-Lex Database

J-Lex (db.tasakipharma.com) is an English-language database of Japanese approved ethical medicines. Procurement teams can search by active ingredient or disease area to identify Japan-approved products relevant to their rare disease patient population.

How TASAKI PHARMA Supports Rare Disease Procurement

TASAKI PHARMA is a Taiwan-based pharmaceutical trading company with GDP and PIC/S GMP-compliant operations, with experience supplying Japan-origin pharmaceuticals—including orphan-designated products—to healthcare institutions in Australia, Hong Kong, the United Kingdom, and Singapore.

• Access to Japan-approved ethical medicines and orphan drug products via J-Lex (db.tasakipharma.com)
• Certificate of Origin (CoO) and product documentation upon request
• GDP-compliant cold chain logistics with temperature data loggers
• Ex Works pricing in USD, EUR, or JPY
• Standard export documentation for customs and regulatory compliance

For enquiries regarding specific rare disease products, contact TASAKI PHARMA via tasakipharma.com.